Stock Scorer

BioScience Health Innovations, Inc. (BHIC)

BioScience Health Innovations, Inc. reported revenue of 1M USD for the quarter ending 30 June 2026, down 41.0% from 1.8M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 1M -41.0%
Gross Profit Q2 '26 · ending 30 June 2026 659.5K -38.6%
Operating Income Q2 '26 · ending 30 June 2026 -217.9K -147.6%
Net Income Q2 '26 · ending 30 June 2026 -185.8K -140.6%
Cost of Revenue Q2 '26 · ending 30 June 2026 376.9K -44.8%
Operating Cash Flow Q2 '26 · ending 30 June 2026 -541.9K -290.1%
Shares Outstanding Q2 '26 · ending 30 June 2026 11.7M -73.6%
EPS Q2 '26 · ending 30 June 2026 -0.03 -150.0%

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 5.7M719.1K642.1K—
20242024-12-31 1.8M87K87K—
20232023-12-31 597.6K-251.5K-251.5K—
20222022-12-31 69.3K-170.4K-170.4K—

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-301M
Q1 '262026-03-31750.9K
Q4 '252025-12-311.6M
Q3 '252025-09-301.1M
Q2 '252025-06-301.8M
Q1 '252025-03-311.2M
Q4 '242024-12-31610.2K
Q3 '242024-09-30573K
Q2 '242024-06-30384.2K
Q1 '242024-03-31277.6K
Q4 '232023-12-31303.6K
Q3 '232023-09-30192.2K
Q2 '232023-06-3069.5K
Q1 '232023-03-3132.3K
Q1 '232023-02-280
Q4 '222022-12-3141.3K
Q4 '222022-11-300
Q3 '222022-09-3019.7K
Q3 '222022-08-310
Q2 '222022-06-308K

Gross Profit Quarterly

PeriodEndingGross Profit
Q2 '262026-06-30659.5K
Q1 '262026-03-31485.6K
Q4 '252025-12-31571.9K
Q3 '252025-09-30698.2K
Q2 '252025-06-301.1M
Q1 '252025-03-31896.1K
Q4 '242024-12-31339K
Q3 '242024-09-30424.7K
Q2 '242024-06-30310.4K
Q1 '242024-03-31234.8K
Q4 '232023-12-31236.5K
Q3 '232023-09-30160.3K
Q2 '232023-06-3060K
Q1 '232023-03-3127.6K
Q4 '222022-12-3136K
Q3 '222022-09-3016.4K
Q2 '222022-06-307.1K
Q1 '222022-03-31214

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-217.9K
Q1 '262026-03-31-229.9K
Q4 '252025-12-31-156.7K
Q3 '252025-09-30-8.8K
Q2 '252025-06-30457.7K
Q1 '252025-03-31426.8K
Q4 '242024-12-3110K
Q3 '242024-09-3056.2K
Q2 '242024-06-3074.2K
Q1 '242024-03-31-53.4K
Q4 '232023-12-31-38.4K
Q3 '232023-09-30-57.1K
Q2 '232023-06-30-85.3K
Q1 '232023-03-31-70.7K
Q1 '232023-02-28-20K
Q4 '222022-12-31-79.7K
Q4 '222022-11-30-28.9K
Q3 '222022-09-30-84.7K
Q3 '222022-08-31-3.7K
Q2 '222022-06-30-1.9K

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-185.8K
Q1 '262026-03-31-229.9K
Q4 '252025-12-31-233.6K
Q3 '252025-09-30-8.8K
Q2 '252025-06-30457.7K
Q1 '252025-03-31426.8K
Q4 '242024-12-3110K
Q3 '242024-09-3056.2K
Q2 '242024-06-3074.2K
Q1 '242024-03-31-53.4K
Q4 '232023-12-31-38.4K
Q3 '232023-09-30-57.1K
Q2 '232023-06-30-85.3K
Q1 '232023-03-31-70.7K
Q1 '232023-02-28-20K
Q4 '222022-12-31-79.7K
Q4 '222022-11-30-28.9K
Q3 '222022-09-30-84.7K
Q3 '222022-08-31-3.7K
Q2 '222022-06-30-1.9K

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262026-06-30376.9K
Q1 '262026-03-31265.4K
Q4 '252025-12-311M
Q3 '252025-09-30433.2K
Q2 '252025-06-30683K
Q1 '252025-03-31330.9K
Q4 '242024-12-31271.2K
Q3 '242024-09-30148.2K
Q2 '242024-06-3073.8K
Q1 '242024-03-3142.8K
Q4 '232023-12-3167.1K
Q3 '232023-09-3031.8K
Q2 '232023-06-309.5K
Q1 '232023-03-314.7K
Q4 '222022-12-315.3K
Q3 '222022-09-303.3K
Q2 '222022-06-30982
Q1 '222022-03-3165

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-541.9K
Q1 '262026-03-31-552.1K
Q4 '252025-12-31-100.7K
Q3 '252025-09-30-340.4K
Q2 '252025-06-30285K
Q1 '252025-03-31328.3K
Q4 '242024-12-31-50.3K
Q3 '242024-09-3052.2K
Q2 '242024-06-3069.3K
Q1 '242024-03-31-48K
Q4 '232023-12-31-56.5K
Q3 '232023-09-30-70.4K
Q2 '232023-06-30-114.3K
Q1 '232023-03-31-66.7K
Q1 '232023-02-28-19.6K
Q4 '222022-12-31-81.7K
Q4 '222022-11-30-27.9K
Q3 '222022-09-30-89.9K
Q3 '222022-08-31-8.2K
Q2 '222022-06-30-10.2K

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-3011.7M
Q1 '262026-03-3111.4M
Q3 '252025-09-3011M
Q2 '252025-06-3011.4M
Q1 '252025-03-3144.3M
Q3 '242024-09-3010.9M
Q2 '242024-06-3042M
Q1 '242024-03-3141.4M
Q3 '232023-09-3040.4M
Q1 '232023-02-285.5M
Q1 '222022-02-285.5M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-0.03
Q1 '262026-03-310.03
Q4 '252025-12-310.06
Q3 '252025-09-300.05
Q2 '252025-06-300.06
Q1 '252025-03-310.02
Q4 '242024-12-310.01
Q3 '242024-09-300.01
Q2 '242024-06-300.00
Q1 '212021-02-280.00
Q4 '202020-11-300.00
Q3 '202020-08-310.00